DIPHOSPHONATE MK-217 FOR PREVENTION OF BONE LOSS DURING EARLY MENOPAUSE

二磷酸盐 MK-217 用于预防绝经早期骨质流失

• 批准号: 6281853
• 负责人: GHADA E FULEIHAN
• 金额: $ 4.73万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6281853
• 关键词: arm; chemoprevention; clinical research; diphosphonate; female; hip; human subject; human therapy evaluation; menopause; oral administration; osteoporosis; pathologic bone resorption; skeletal disorder chemotherapy; skeletal pharmacology; spine

This is a randomized, placebo-controlled dose ranging study to evaluate the safety and efficacy of the new oral diphophonate MK-217 when given to early postmenopausel women. The hypothesis to be tested is that daily oral administration of MK-217 will prevent bone loss in the spine, hip and forearm when compared to placebo-treated control.

这是一项随机、安慰剂控制的剂量范围研究